cysteamine has been researched along with Dermatitis, Atopic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SE; Choi, YW; Eum, JY; Kang, KH; Kang, MH; Kang, MJ; Lee, MW; Oh, CH; Park, KH; Park, SH | 1 |
| Ahn, EH; Choi, SY; Eum, WS; Jeong, HJ; Kang, HW; Kim, DW; Kim, MJ; Kim, SY; Kim, TY; Kim, YN; Kwon, HJ; Kwon, SW; Lee, KS; Park, J; Shin, MJ; Sohn, EJ | 1 |
2 other study(ies) available for cysteamine and Dermatitis, Atopic
| Article | Year |
|---|---|
Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cysteamine; Dermatitis, Atopic; Disease Models, Animal; Drug Carriers; Elasticity; Excipients; Glucosides; Liposomes; Male; Mice; Mice, Inbred ICR; Peptides; Permeability; Quercetin; Skin Absorption | 2010 |
Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice.
Topics: Animals; Cysteamine; Dermatitis, Atopic; Disease Models, Animal; Immunoglobulin E; Interferon-gamma; MAP Kinase Signaling System; Mice; NF-kappa B; Peptides; Recombinant Fusion Proteins; Tacrolimus Binding Proteins; Tumor Necrosis Factor-alpha | 2011 |